Australia:NRT

Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma

SYDNEY, Nov. 18, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a summary of new paxalisib data presented at the Society for Neuro-Oncology (SNO) Annual Meeting, which is being held virtually from...

2020-11-18 07:39 1961

GDC-0084 Progress Update: On Track for Phase II Commencement in 2017

SYDNEY, Aug. 22, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc inOcto...

2017-08-22 12:06 1804

Board Review of Business Operations and Governance

SYDNEY, Aug. 14, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appo...

2017-08-14 11:02 2615

Progress Update on Cantrixil(TM) (TRXE-002-1) Development

SYDNEY, Aug. 7, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Phase I Clinical Trial in Ovarian Cancer Pro...

2017-08-07 11:03 2256

Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure

- Recent in-licensing of GDC-0084 and advancement of Cantrixil to phase I represent transformation of Novogen to clinical-stage organisation; recent appointments of Chief Medical Officer and Head of CMC position Novogen for success in these activities - Dr David Brown, Chief Scientific Officer...

2017-03-10 09:21 3348

Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program

SYDNEY, March 6, 2017 /PRNewswire/ -- * Grant is provided under Cooperative Research Centre Project (CRC-P) scheme and provides up toA$3 million in cash over three years * Funds will be applied to development of a next-generation anti-tropomyosin program, intended to provide potential new ...

2017-03-06 18:54 2265

Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma

SYDNEY, Oct. 31, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company, Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has fully-acquired Glioblast Pty Ltd, a privately-held, neuro-oncology-focused Australian biotechnology company. The transaction includes ...

2016-10-31 11:54 2098

Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma

SYDNEY, Oct. 31, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company, Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has entered into a worldwide licensing agreement with Genentech, a member of the Roche Group, to develop and commercialise GDC-0084, a small ...

2016-10-31 11:40 1842

Conversion of Convertible Notes

SYDNEY, Sept. 14, 2016 /PRNewswire/ -- On 19 April 2013, the shareholders of Novogen Limited approved the issue of 60,000,000 convertible securities, with a face value of$1.5M, to the former securities holders of Triaxial Pharmaceuticals Pty Ltd. The conversions of the convertible notes are cont...

2016-09-14 12:07 1905

US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer

SYDNEY, Sept. 12, 2016 /PRNewswire/ -- * Cantrixil (TRX-E-002-1) is Novogen's lead development candidate, and is being developed as an intraperitoneal therapy for patients with ovarian cancer * Investigational New Drug (IND) application is the key regulatory filing to initiate clinical trial...

2016-09-12 11:00 2103

Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer

SYDNEY, Aug. 11, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for Cantrixil (TRX-E-002...

2016-08-11 13:59 2734

Novogen Patent Covering Anisina(TM) Has Proceeded to Grant

SYDNEY, June 14, 2016 /PRNewswire/ -- US-Australian drug discovery company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that a patent for the ATM-3500 series had been granted inAustralia. The ATM-3500 series includes the investigational agent known as Anisina (ATM-3507). Novogen North Am...

2016-06-14 08:30 2382

Novogen Provides Update On Development Of Cantrixil

SYDNEY, May 2, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian canc...

2016-05-02 10:43 2628

Novogen Receives R&D Tax Incentive Cash Refund

SYDNEY, March 17, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that it has received a cash refund of$2.8M from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending30 June 2015. This wi...

2016-03-17 10:27 2618

Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant

SYDNEY, Feb. 19, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that a patent for the superbenzopyran (SBP) family, covering the lead candidates Cantrixil and Trilexium, has been granted inAustralia. This patent provides full prot...

2016-02-19 14:18 2474

Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed

SYDNEY, Feb. 5, 2016 /PRNewswire/ -- Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the appointment of a new Chairman, MrJohn O'Connor, and new Deputy Chairman, Mr Bryce Carmine, effective immediately. Incoming CEO, Dr James G...

2016-02-05 15:31 3103

Novogen Appoints Dr James Garner as Chief Executive Officer

SYDNEY, Dec. 10, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the appointment of Dr James Garner as Chief Executive Officer. Dr Garner will take up the role on 1 February 2016, at which time he will be appointed to the Board of D...

2015-12-10 06:02 3411

Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial

SYDNEY, Nov. 24, 2015 /PRNewswire/ -- * Novogen engages Novotech as CRO for upcoming Phase 1 clinical study * Cantrixil Phase 1 clinical trial to be conducted in patients with refractory/recurrent peritoneal malignancies with malignant ascites, including ovarian cancer US-Australian drug dis...

2015-11-24 08:38 2350

Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia

SYDNEY, Nov. 12, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ: NVGN) today announced that a patent application covering two of its key lead superbenzopyran (SBP) drug candidates has been accepted in Australia.  According to Novogen North Ameri...

2015-11-12 08:04 2025

Novogen Applies for Long-term Options Listing

SYDNEY, Sept. 30, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today announced that it will apply for the listing of the Long-Term Options on ASX and anticipates that this request will be granted within the next week. An Appendix 3B has been ...

2015-09-30 10:52 2447
123